Go to
JCI Insight
Citations to this article
S Gupta, … , J Kim, S Gollapudi
Published April 1, 1991
Citation Information: J Clin Invest. 1991;87(4):1467-1469. https://doi.org/10.1172/JCI115154.
Citation Information: J Clin Invest. 1991;87(4):1467-1469. https://doi.org/10.1172/JCI115154.
Abstract
Itraconazole is a recently developed triazole antifungal agent that inhibits cell membrane sterol biosynthesis. Itraconazole, in a dose-dependent manner, enhanced intracellular accumulation of daunorubicin and reversed the drug resistance in murine leukemia P388/ADR cells. In addition, itraconazole corrected the altered plasma membrane potentials of P388/ADR cells. The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections. Therefore, itraconazole is a potential candidate for in vivo use to reverse multidrug resistance in cancer with added benefit of its antifungal property.
Authors
S Gupta, J Kim, S Gollapudi
Total citations by year
Citation information
Citations to this article in year 2017 (3)
| Title and authors | Publication | Year |
|---|---|---|
|
Repurposing itraconazole as an anticancer agent
H Tsubamoto, T Ueda, K Inoue, K Sakata, H Shibahara, T Sonoda |
Oncology Letters | 2017 |
|
Repurposing itraconazole for the treatment of cancer
R Pounds, S Leonard, C Dawson, S Kehoe |
Oncology Letters | 2017 |
|
Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation
HM Treshalina, VI Romanenko, DN Kaluzhny, MI Treshalin, AA Nikitin, AS Tikhomirov, AE Shchekotikhin |
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences | 2017 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)